

Pfizer will present **more than 50 abstracts, involving more than 15 clinical-stage assets across solid and hematologic tumors and 12 moA**, at the ASCO in Chicago from June 2-6, 2017.

New data will be featured in 9 oral presentations from company-sponsored clinical trials, including a **late-breaker on the investigational compound dacomitinib in locally advanced or metastatic NSCLC** with EGFR-activating mutation, which will be featured in the official ASCO press program. Other abstracts provide insights into treating lung, breast, kidney and prostate cancers and hematologic malignancies across marketed and investigational Pfizer therapies, including immuno-oncology (IO) and IO combinations.

Key Trial Readouts

Hematology	<ul style="list-style-type: none"> Bosutinib versus imatinib for newly diagnosed CML: initial results from the phase 3 BFORE trial (Abstract# 7002) Factors associated with allogeneic hematopoietic stem cell transplantation outcomes in pts with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin vs. conventional chemotherapy (Abstract# 7007)
Lung cancer	<ul style="list-style-type: none"> Randomized, open-label phase 3 study of Dacomitinib versus gefitinib for the 1L treatment of advanced EGFRm+ NSCLC: ARCHER 1050 (Abstract# LBA9007) Efficacy and safety of lorlatinib in ALK+ NSCLC patients with ≥1 prior ALK tyrosine kinase inhibitor: A phase I/II study (Abstract# 9006)
Breast cancer	<ul style="list-style-type: none"> Results of a phase 2 study of talazoparib following platinum or multiple cytotoxic regimens in advanced breast cancer patients with germline BRCA1/2 mutations (ABRAZO) (Abstract# 1007) OS results from the phase 2 study of palbociclib in combination with letrozole vs letrozole alone for 1L treatment of ER+/HER2- advanced breast cancer (PALOMA-1; TRIO-18) (Abstract# 1001)
Renal cell carcinoma	<ul style="list-style-type: none"> 1L avelumab + axitinib in patients with advanced renal cell carcinoma (aRCC): Phase 1b trial (Abstract# 4504) P3 trial of adjuvant sunitinib in pts with high-risk RCC: validation of the 16-gene Recurrence Score in stage III patients (Abstract# 4508)
Prostate cancer	<ul style="list-style-type: none"> New clinical data provide insights into combination of agents most likely to benefit pts with mCRPC following PSA progression with enzalutamide, adding to the robust and rigorous clinical trial program of XTANDI® in mCRPC and other prostate cancer populations.

CORPORATE COMMUNICATIONS



*While tremendous strides in cancer are made every day, it's clear there is so much more to achieve on behalf of patients," said **Liz Barrett, Global President and General Manager, Pfizer Oncology.** "Through our cutting-edge science and a desire to work collaboratively, Pfizer Oncology continues to break boundaries in cancer care and is helping to redefine life with cancer."*

*"Our presentations at this year's ASCO cover a broad range of drug development: from Phase 1 to Phase 3; from immunotherapy to targeted agents and antibody-drug conjugates; from disease areas in which we have extensive experience to disease areas that we are entering for the first time," said **Mace Rothenberg, MD, Chief Development Officer, Oncology, Pfizer Global Product Development.** "We are very excited about sharing these results with the oncology community and working with them to realize the full potential of our medicines."*